{"brief_title": "A Phase I Study of Subcutaneously Administered Proleukin (Aldesleukin) in HIV-Infected Patients", "brief_summary": "To determine the MTD and dose-limiting toxicities of recombinant interleukin-2 (aldesleukin; Proleukin) administered subcutaneously in HIV-seropositive patients. To identify a tolerable subcutaneous regimen that will replicate the immunologic improvement demonstrated in the outpatient polyethylene glycolated IL-2 and high-dose continuous infusion IL-2 studies. To evaluate the incidence and level of anti-IL-2 antibody formation to subcutaneously administered Proleukin in this patient population.", "detailed_description": "Patients will receive subcutaneous Proleukin, and the MTD will be determined.", "condition": ["HIV Infections"], "intervention_type": ["Drug"], "intervention_name": ["Aldesleukin"], "criteria": "Inclusion Criteria Patients must have: - Documented HIV infection by ELISA and Western blot. - CD4 count > 200 cells/mm3. Required: - FDA-approved antiretroviral therapy for at least 2 months prior to study entry.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "AIDS-Related Complex", "mesh_term": ["HIV Infections", "Aldesleukin", "Interleukin-2"], "id": "NCT00002107"}